Thyrocare Technologies Ltd · NSE:THYROCARE
Thyrocare Technologies — Q2 FY2020 Earnings Presentation
10 slides from Thyrocare Technologies's earnings presentation, Nov 7, 2019
Slide 1: Thyrocare - Think Thyroid. Think Thyrocare.
Thyrocare Think Thyroid. Think Thyrocare. November 07, 2019 The National Stock Exchange of India Limited The Bombay Stock Exchange Ltd Exchange Plaza Phiroze Jeejeeboy Towers Bandra Kurla Complex, Dalal Street, Bandra (E), Mumbai - 400 051 Mumbai- 400 001 Dear Sirs, Sub: Presentation on Quarterly Re
Slide 2: Disclaimer
Disclaimer This presentation is for information purposes only and it contains general background information about the Company’s activities. The Company assumes no responsibility to publicly amend, modify or revise any forward looking statements on the basis of any subsequent development, informatio
Slide 3: Highlights - Financial Performance - Thyrocare
Highlights - Financial Performance - Thyrocare Revenue from operations (in crore) Revenue Revenue Revenue from operations Q2-20 - Rs. 107.9 crore (+13%) growth growth [Q2-19 - Rs. 95.7 crore] 13% QYOY 208.4 13% HYOY 184.9 Samples processed Q2-20 – 0.52 crore (+5%) Samples Samples growth 107.9 [Q2-19
Slide 4: Highlights - Financial Performance - Thyrocare (Continued..)
Highlights - Financial Performance – Thyrocare (Continued..) EBITDA Q2-20- Rs. 50.2 crore (+23%) (EBITDA margin 47%) [Q2-19 - Rs. 40.7 crore ] Normalised EBITDA margin – 45% [Q2-19 – 44% ] PAT Q2-20 - Rs. 37.4 crore (+41%) (PAT margin 35%) [Q2-19- Rs. 26.6 crore] Q1 29.1% 9.8% 16.2% 44.9% Q5 30.0% 9
Slide 5: Highlights - Operational Performance - Pathology
Q2 revenue by nature Q2 revenue by type Highlights - Operational Performance - Pathology (in crore) (in crore) Wellness Value Q2-20 - Rs. 52.6 crore (52%) [Q2-19- Rs. 46.0 crore (50%)] 23.5 - Wellness Volume Q2-20 – 7.6 lakhs (15% of total samples) [Q2-19 – 6.6 lakhs (13% of total 20.05 48.38 sample
Slide 6: Highlights - Financial Performance - Nueclear
Highlights - Financial Performance - Nueclear Revenue from operations (in crore) 18.1 Revenue from operations Q2-20 - Rs. 8.6 crore (+5%) [Q2-19 - Rs. 8.2 16.2 crore] - Revenue from imaging services Q1-20 - Rs. 7.9 crore (+4%) [Q2-19 - Rs. 7.6 crore] - Operations at two centres in Gujarat were non f
Slide 7: Highlights - Financial Performance - Nueclear
Highlights - Financial Performance - Nueclear Employee benefits expense Employee/ consultant costs increased mainly on account of the centres newly started. Normalised EBITDA Q2-20 - Rs. 0.9 crore (EBITDA margin 11%) [Q2-19 - Rs. 1.9 crore (23%)] Other expenses More machines covered under maintenanc
Slide 8: Highlights - Financial Performance - Consolidated
Revenue from operations (in crore) Highlights - Financial Performance - Consolidated Revenue Revenue growth growth 12% 12% Revenue from operations Q2-20 - Rs. 116.2 crore (+12%) [Q2-19 - QYOY HYOY 208.4 Rs. 103.9 crore] 184.9 Normalised EBITDA Q2-20 - Rs. 49.5 crore (EBITDA margin Consolidated 43%)
Slide 9: Adoption of Ind AS 116 'Leases'
Adoption of Ind AS- 116 “Leases” The Company has adopted Indian Accounting Standard 116 - Leases ("Standard"), with effect from 1 April 2019 using the modified retrospective method under the transitional provisions of the Standard and has taken the cumulative adjustment to retained earnings as on 1
Slide 10: Thank You
Tnank You
Thyrocare Technologies — Q2 FY2020 Earnings Presentation on 6ix